The estimated Net Worth of Ram Mukunda is at least $1.91 Milione dollars as of 13 March 2024. Mr Mukunda owns over 1,184,585 units of IGC Pharma Inc stock worth over $303,627 and over the last 16 years he sold IGC stock worth over $806,197. In addition, he makes $801,000 as Exec. Chairman e Pres & CEO at IGC Pharma Inc.
Mr has made over 11 trades of the IGC Pharma Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,184,585 units of IGC stock worth $443,627 on 13 March 2024.
The largest trade he's ever made was exercising 1,184,585 units of IGC Pharma Inc stock on 13 March 2024 worth over $443,627. On average, Mr trades about 162,103 units every 173 days since 2009. As of 13 March 2024 he still owns at least 810,752 units of IGC Pharma Inc stock.
You can see the complete history of Mr Mukunda stock trades at the bottom of the page.
Ram Mukunda is the Exec. Chairman, Pres & CEO at IGC Pharma Inc.
As the Exec. Chairman e Pres & CEO of IGC Pharma Inc, the total compensation of Mr Mukunda at IGC Pharma Inc is $801,000. There are no executives at IGC Pharma Inc getting paid more.
Mr Mukunda is 62, he's been the Exec. Chairman e Pres & CEO of IGC Pharma Inc since . There are no older and 5 younger executives at IGC Pharma Inc.
Over the last 17 years, insiders at IGC Pharma Inc have traded over $12,397,736 worth of IGC Pharma Inc stock and bought 1,543,722 units worth $473,972 . The most active insiders traders include Ram Mukunda, Steven Michael Oliveira e Zwirn & Co., L.P.Zwirn Dani.... On average, IGC Pharma Inc executives and independent directors trade stock every 143 days with the average trade being worth of $93,624. The most recent stock trade was executed by Ram Mukunda on 13 March 2024, trading 1,184,585 units of IGC stock currently worth $443,627.
igc is developing a product portfolio of phytocannabinoid-based therapies through leading edge research for the treatment of a wide range of therapeutic indications. these include neuropathic and cancer pain, epilepsy, end of life supportive care, adjunctive supportive therapies of chronic neurological and oncological diagnosis, which are life altering or life threatening our mission is to treat pain, ptsd, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions with phytocannabinoid-based treatments
IGC Pharma Inc executives and other stock owners filed with the SEC include: